CNS Pharmaceuticals, Inc. Proceeds from Issuance or Sale of Equity
CNS Pharmaceuticals, Inc. (CNSP) reported Proceeds from Issuance or Sale of Equity of $500.88 thousand for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-14.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOrSaleOfEquity · last filed 2026-05-14
- CNS Pharmaceuticals, Inc. proceeds from issuance or sale of equity for the quarter ending 2026-03-31 was $500.88K, a 94.46% decline year-over-year.
- CNS Pharmaceuticals, Inc. proceeds from issuance or sale of equity for the quarter ending 2025-03-31 was $9.03M.
- CNS Pharmaceuticals, Inc. proceeds from issuance or sale of equity for fiscal 2019 was $0.00, a 100.00% decline from fiscal 2018.
- CNS Pharmaceuticals, Inc. proceeds from issuance or sale of equity for fiscal 2018 was $586.67K.
| Period end | Proceeds from Issuance or Sale of Equity 0 month | Proceeds from Issuance or Sale of Equity 3 month | Proceeds from Issuance or Sale of Equity 12 month |
|---|---|---|---|
| 2026-03-31 | $500.88K 10-Q · filed 2026-05-14 | ||
| 2025-03-31 | $9.03M 10-Q · filed 2026-05-14 | ||
| 2024-02-01 | $3.33M 10-Q · filed 2024-08-14 | ||
| 2019-12-31 | $0.00 10-K · filed 2020-03-12 | ||
| 2018-12-31 | $586.67K 10-K · filed 2020-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |